Select Language

TIGIT

TIGIT Overview

English Name	T cell immunoglobulin and ITIM domains	Approved Drugs	0
Drugs in Clinical Trials	40	Target Synonym	V-Set And Immunoglobulin Domain Containing 9，Washington University Cell Adhesion Molecule，V-Set And Transmembrane Domain Containing 3，WUCAM，DKFZp667A205，FLJ39873，V-set and immunoglobulin domain-containing protein 9，TIGIT，VSIG9，T Cell Immunoreceptor With Ig And ITIM Domains，V-Set And Transmembrane Domain-Containing Protein 3，VSIG9， VSTM3，VSTM3，T-Cell Immunoreceptor With Ig And ITIM Domains
Highest Development Stage	Phase 3 Clinical

English Name	T cell immunoglobulin and ITIM domains
Target Synonym	V-Set And Immunoglobulin Domain Containing 9，Washington University Cell Adhesion Molecule，V-Set And Transmembrane Domain Containing 3，WUCAM，DKFZp667A205，FLJ39873，V-set and immunoglobulin domain-containing protein 9，TIGIT，VSIG9，T Cell Immunoreceptor With Ig And ITIM Domains，V-Set And Transmembrane Domain-Containing Protein 3，VSIG9， VSTM3，VSTM3，T-Cell Immunoreceptor With Ig And ITIM Domains
Approved Drugs	0
Drugs in Clinical Trials	40
Highest Development Stage	Phase 3 Clinical

TIGIT Product List

Product Category
Protein (18)Antibody (1)
Product Status
Launched (19)
Species
Human (7)Mouse (4)Cynomolgus / Rhesus macaque (5)Rat (1)Canine (1)Rabbit (1)
Tag
Fc Tag (4)His Tag (5)Fc Tag & Avi Tag (3)Mouse IgG Fc Tag (2)Mouse IgG Fc Tag & Avi Tag (1)His Tag & Avi Tag (3)- (1)
Conjugate
Unconjugated (10)Biotin-labeled (7)PE Labeled (2)

Cat. No.	Species	Host	Product Description
HOT TIT-H5253	Human	HEK293	Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
HOT TIT-H5254	Human	HEK293	Human TIGIT Protein, Fc Tag, low endotoxin (MALS verified)
HOT TIT-H52H5	Human	HEK293	Human TIGIT Protein, His Tag, active dimer, low endotoxin (MALS verified)
HOT TIT-H82E6	Human	HEK293	Biotinylated Human TIGIT Protein, His,Avitag™, active dimer (recommended for biopanning) (MALS verified)
HOT TIT-H82F1	Human	HEK293	Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-H82F3	Human	HEK293	Biotinylated Human TIGIT Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
TIT-HP2H3	Human	HEK293	PE-Labeled Human TIGIT Protein, His TagStar Staining
TIT-M5257	Mouse	HEK293	Mouse TIGIT Protein, Fc Tag (MALS verified)
TIT-M52E6	Mouse	HEK293	Mouse TIGIT Protein, His Tag (MALS verified)
TIT-M82E9	Mouse	HEK293	Biotinylated Mouse TIGIT Protein, His,Avitag™, active dimer (MALS verified)

Total: 19

TIGIT Background

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

TIGIT Synonyms

TIGIT,VSIG9,VSTM3

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Vibostolimab	MK-7684	Phase 3 Clinical	Merck Sharp & Dohme Corp	Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Solid tumours	Details
Domvanalimab	GS-0154; AB-154	Phase 3 Clinical	Abmuno Therapeutics LLC	Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Liver Neoplasms; Lung Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms	Details
Tiragolumab	MTIG-7192A; RO-7092284; RG6058-11; RG6058-10; RG-6058	Phase 3 Clinical	Genentech Inc	Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Microsatellite instability-high cancer; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Oral Squamous Cell Carcinoma; Rectal Neoplasms; Rhabdoid Tumor; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Teratoma; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
Pembrolizumab/Vibostolimab	MK-7684A	Phase 3 Clinical	Merck & Co Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
SHS-006(Nanjing Sanhome Pharmaceutical)	SHS-006; SH-006; SH006	Phase 3 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours	Details
Rilvegostomig	AZD-2936	Phase 3 Clinical	Astrazeneca Plc	Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
Belrestotug	EOS-884448; GSK-4428859; GSK-4428859A; EOS-448	Phase 3 Clinical	Iteos	Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Solid tumours	Details
HL-301	HL-301	Phase 3 Clinical	Hanmi Pharmaceutical Co Ltd	Acute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis	Details
Ociperlimab	WCD-118; BGB-A1217	Phase 3 Clinical	BeOne Medicines Ltd	Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms	Details
Etigilimab	OMP-313M32	Phase 2 Clinical	Oncomed Pharmaceuticals Inc	Adenocarcinoma, Clear Cell; Fallopian Tube Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours	Details
Renvistobart	BMS-986207; ONO-4686	Phase 2 Clinical	Bristol-Myers Squibb Company	Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours	Details
Nilvanstomig	ZG-005	Phase 2 Clinical	Gensun Biopharma Inc	Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms	Details
AK-130	AK-130	Phase 2 Clinical		Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
HB-0036	HB-0036	Phase 2 Clinical	HuaBo Biopharm Co Ltd	Carcinoma, Non-Small-Cell Lung; Solid tumours	Details
HY-07121	HY-07121; HY07121	Phase 2 Clinical	Sichuan Huiyu Seacross Pharma Technology Ltd	Solid tumours	Details
PM-1022	PM-1022	Phase 2 Clinical		Neoplasms	Details
Lancastotug	AK-127	Phase 2 Clinical		Carcinoma, Hepatocellular; Neoplasms; Solid tumours	Details
HLX-301	HLX-301	Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
HLX-53	HLX-53; HLX53	Phase 2 Clinical		Carcinoma, Hepatocellular; Lymphoma; Solid tumours	Details
PM-1009	PM1009	Phase 2 Clinical		Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours	Details
Dargistotug	M-6223; M6223	Phase 2 Clinical	Emd Serono Research & Development Institute Inc	Carcinoma, Transitional Cell; Solid tumours	Details
DW-2008	DW-2008; DW-2008S	Phase 1 Clinical	Dong Wha Pharm Co Ltd	Asthma; Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic	Details
Tamgiblimab	IBI-939	Phase 1 Clinical		Lung Neoplasms; Neoplasms	Details
COM-902	COM-902; CGEN-15137	Phase 1 Clinical	Compugen Ltd	Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck	Details
HY-0007	HY-0007	Phase 1 Clinical	Sichuan Huiyu Pharmaceutical Co Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours	Details
SIM-0348	SIM-0348	Phase 1 Clinical	Simcere Pharmaceutical Group Ltd	Neoplasms; Solid tumours	Details
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma)	LP-010	Phase 1 Clinical	Lepu Biopharma Co Ltd	Solid tumours	Details
ASP-8374	ASP-8374; PTZ-201	Phase 1 Clinical	Astellas Pharma Inc, Potenza Therapeutics	Glioblastoma; Solid tumours	Details
BMS-986442	AGEN-1777; BMS-986442; BMS-986-442	Phase 1 Clinical	Agenus Inc	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms	Details
LNF-1802	LNF1802; LNF-1802	Phase 1 Clinical	Shandong New Time Pharmaceutical Co Ltd	Neoplasms	Details
ZGGS-15	ZGGS15; ZGGS-15	Phase 1 Clinical	Suzhou Zelgen Biopharmaceuticals Co Ltd	Solid tumours	Details
AUR-106	AUR-106	Phase 1 Clinical	Aurigene Discovery Technologies Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms	Details
BC008-1A	BC008-1A	Phase 1 Clinical	Sichuan Luzhou Buchang Biopharmaceutical Co Ltd	Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Glioma; Solid tumours	Details
SHR-2002	SHR-2002	Phase 1 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd	Neoplasms	Details
PM-1021	PM1021	Phase 1 Clinical		Neoplasms	Details
HH-101	HH-101	Phase 1 Clinical	Huahui Health Ltd	Solid tumours	Details
HB0030	HB-0030	Phase 1 Clinical	HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd	Solid tumours	Details
BAT-6005	BAT-6005	Phase 1 Clinical	Bio-Thera Solutions Ltd	Solid tumours	Details
IBI-321	IBI-321	Phase 1 Clinical		Neoplasms; Solid tumours	Details
Ralzapastotug	AB-308	Phase 1 Clinical	Arcus Biosciences Inc	Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms	Details

Product Reviews

1***32019-10-11
3People Like
Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
I have used Acro products in other projects, and the quality is comparable to RnD Systems products. The purpose of buying this protein was mainly for immunization and screening, and we finally got candidate molecules.